Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice

Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

(2021) Matteo Megna et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison

(2021) Angelo Ruggiero et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A case of erythrodermic psoriasis successfully treated with guselkumab

(2020) Matteo Megna et al.   Dermatologic Therapy

Safety concerns with current treatments for psoriasis in the elderly

(2020) Roberta Di Caprio et al.   Expert Opinion On Drug Safety

Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review

(2020) Vijay Kumari Sandhu et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2‐year period

(2020) M. Megna et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: preliminary data of a real‐life 16‐week retrospective study

(2020) Matteo Megna et al.   Dermatologic Therapy

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience

(2020) Matteo Megna et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

(2020) Marco Galluzzo et al.   Journal of Clinical Medicine

Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study

(2020) Angelo Ruggiero et al.   Dermatologic Therapy

Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis

(2019) J.J. Crowley et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1‐year period

(2019) M. Megna et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

(2018) Andreas Körber et al.   DRUGS & AGING

Elderly psoriatic patients under biological therapies: an Italian experience

(2018) F Ricceri et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly

(2018) Vito Di Lernia et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

(2018) Kenneth B Gordon et al.   LANCET

How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol

(2018) Vicenç Torrente-Segarra et al.   RHEUMATOLOGY INTERNATIONAL

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period

(2016) M. Megna et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Overview of biologic treatments in the elderly

(2015) Clément Lahaye et al.   JOINT BONE SPINE

Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients

(2014) S Piaserico et al.   ACTA DERMATO-VENEREOLOGICA

Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis

(2014) Mitsuha Hayashi et al.   JOURNAL OF DERMATOLOGY

Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study

(2012) Maria Esposito et al.   DERMATOLOGY

Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?

(2011) Hyuck Hoon Kwon et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation

(2011) Ivan S. Grozdev et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

(2010) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY